Fixed-ratio combination oxycodone/naloxone compared with oxycodone alone for the relief of opioid-induced constipation in moderate-to-severe noncancer pain
The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Opioid therapy is frequently associated with treatment-limiting constipation. Naloxone is an opioid antagonist with low oral systemic bioavailability. This Phase III clinical trial assessed the safety and efficacy of an oral fixed-ratio combination of oxycodone prolonged-release (PR) and naloxone PR compared with oxycodone PR in relieving opioid-induced constipation. STUDY DESIGN: This double-blind, multicenter trial was conducted in specialist and primary care centers in four European countries in an out-patients setting. The study included 322 adult patients with moderate-to-severe, noncancer pain requiring opioid therapy in a range of >or=20 mg/day and <or=50 mg/day oxycodone. Following a run-in phase patients were randomized to receive oxycodone PR/naloxone PR or oxycodone PR for 12 weeks. The primary outcome was improvement in constipation as measured using the Bowel Function Index (BFI). Secondary/exploratory assessments focused on pain intensity and additional bowel parameters. TRIAL REGISTRATION: NCT00412152. RESULTS: A significant improvement in BFI scores occurred with oxycodone PR/naloxone PR compared with oxycodone PR after 4 weeks of double-blind treatment (-26.9 vs. -9.4, respectively; p < 0.0001), observed after only 1 week of treatment and continued until study end. A significant increase in the number of complete spontaneous bowel movements and decrease in laxative use were also reported. This improvement in bowel function was achieved without compromising the analgesic efficacy of the oxycodone component; pain intensity remained constant throughout the study. The incidence of adverse events was comparable in both groups and consistent with those expected of opioid analgesics. As the study was limited to a dose range of up to 50 mg oxycodone equivalent per day, further research on higher doses would be recommended. CONCLUSION: The fixed-ratio combination of oxycodone PR/naloxone PR is superior to oxycodone PR alone, offering patients effective analgesia while significantly improving opioid-induced constipation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Strategies to Manage the Adverse Effects of Oral Morphine: An Evidence-Based Report
Cherny, N., Ripamonti, C., Pereira, J., Davis, C., Fallon, M., McQuay, H., Mercadante, S., Pasternak, G., Ventafridda, V., & for the Expert Working Group of the European Association of Palliative Care Network (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.9.2542 · Cited by 626
Methylnaltrexone for Opioid-Induced Constipation in Advanced Illness
Thomas, J., Karver, S., Cooney, G. A., Chamberlain, B. H., Watt, C. K., Slatkin, N. E., Stambler, N., Kremer, A. B., & Israel, R. J. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0707377 · Cited by 595
Opioid-Induced Bowel Dysfunction: Pathophysiology and Potential New Therapies
Kurz, A., & Sessler, D. I. (2003) · Drugs · doi:10.2165/00003495-200363070-00003 · Cited by 587
Incidence, Prevalence, and Management of Opioid Bowel Dysfunction
Pappagallo, M. (2001) · The American Journal of Surgery · doi:10.1016/s0002-9610(01)00782-6 · Cited by 531
Watson, P. C. N., Moulin, D., Watt-Watson, J., Gordon, A., & Eisenhoffer, J. (2003) · Pain · doi:10.1016/s0304-3959(03)00160-x · Cited by 510
Drossman, D. A. (1994) · Medical Entomology and Zoology · Cited by 470
Controlled-release oxycodone for pain in diabetic neuropathy: A randomized controlled trial
Gimbel, J. S., Richards, P., & Portenoy, R. K. (2003) · Neurology · doi:10.1212/01.wnl.0000057720.36503.2c · Cited by 469
Psychometric Validation of a Constipation Symptom Assessment Questionnaire
L. Frank, L. K. (1999) · Scandinavian Journal of Gastroenterology · doi:10.1080/003655299750025327 · Cited by 458
Kalso, E. A. (2005) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2005.01.010 · Cited by 312
Yuan, C.-S., Foss, J. F., O'Connor, M., Osinski, J., Karrison, T., Moss, J., & Roizen, M. F. (2000) · JAMA · doi:10.1001/jama.283.3.367 · Cited by 297
Meissner, W., Leyendecker, P., Mueller‐Lissner, S., Nadstawek, J., Hopp, M., Ruckes, C., Wirz, S., Fleischer, W., & Reimer, K. (2009) · European Journal of Pain · doi:10.1016/j.ejpain.2008.06.012 · Cited by 257
Self-citationWHO guidelines for the use of analgesics in cancer pain.
Ventafridda, V., Saita, L., Ripamonti, C. I., & Conno, F. (1985) · PubMed · Cited by 232
Opioids and the gut: pharmacology and current clinical experience
De Schepper, H. U., Cremonini, F., Park, M. ‐., & Camilleri, M. (2004) · Neurogastroenterology & Motility · doi:10.1111/j.1365-2982.2004.00513.x · Cited by 214
Vondrackova, D., Leyendecker, P., Meissner, W., Hopp, M., Szombati, I., Hermanns, K., Ruckes, C., Weber, S., Grothe, B., Fleischer, W., et al. (2008) · The Journal of Pain · doi:10.1016/j.jpain.2008.06.014 · Cited by 210
Self-citationLow-Dose Oral Naloxone Reverses Opioid-Induced Constipation and Analgesia
Liu, M., & Wittbrodt, E. (2002) · Journal of Pain and Symptom Management · doi:10.1016/s0885-3924(01)00369-4 · Cited by 204
Oral naloxone reverses opioid-associated constipation
Meissner, W., Schmidt, U., Hartmann, M., Kath, R., & Reinhart, K. (2000) · Pain · doi:10.1016/s0304-3959(99)00185-2 · Cited by 204
Sykes, N. (1996) · Palliative Medicine · doi:10.1177/026921639601000208 · Cited by 197
SPILLER, R. (2000) · Gut · doi:10.1136/gut.46.5.741b · Cited by 195
Holzer, P. (2004) · Neuroscience Letters · doi:10.1016/j.neulet.2003.12.004 · Cited by 180
Mucci‐LoRusso, P., Berman, B. S., Silberstein, P. T., Citron, M. L., Bressler, L., Weinstein, S. M., Kaiko, R. F., Buckley, B. J., & Reder, R. F. (1998) · European Journal of Pain · doi:10.1016/s1090-3801(98)90020-9 · Cited by 175
Opioid analgesia: perspectives on right use and utility.
Ballantyne, J. C. (2007) · PubMed · Cited by 157
Choi, Y. S., & Billings, J. A. (2002) · Journal of Pain and Symptom Management · doi:10.1016/s0885-3924(02)00424-4 · Cited by 148
Opioid Analgesia: Perspectives on Right Use and Utility
Ballantyne, J. C. (2007) · Pain Physician · doi:10.36076/ppj.2007/10/479 · Cited by 142
Handal, K. A., Schauben, J. L., & Salamone, F. R. (1983) · Annals of Emergency Medicine · doi:10.1016/s0196-0644(83)80343-6 · Cited by 136
Yuan, C. (2000) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2000.105037 · Cited by 83
(1994) · PubMed
Cited by
Opioid-Induced Constipation and Bowel Dysfunction: A Clinical Guideline
Müller-Lissner, S., Bassotti, G., Coffin, B., Drewes, A. M., Breivik, H., Eisenberg, E., Emmanuel, A., Laroche, F., Meissner, W., & Morlion, B. (2017) · Pain Medicine · doi:10.1093/pm/pnw255 · Cited by 210
Self-citationPharmacological treatment of chronic pain—The need for CHANGE
Varrassi, G., Müller-Schwefe, G., Pergolizzi, J., Orónska, A., Morlion, B., Mavrocordatos, P., Margarit, C., Mangas, C., Jaksch, W., Huygen, F., et al. (2010) · Current Medical Research and Opinion · doi:10.1185/03007991003689175 · Cited by 167
Emerging therapies for patients with symptoms of opioid-induced bowel dysfunction
Leppert, W. (2015) · Drug Design Development and Therapy · doi:10.2147/dddt.s32684 · Cited by 72
“5%), compared to PR oxycodone administered alone.(80) These effects are associated with naloxone antagonist effect on opioid receptors in the GI tract,(81) and prokinetic properties.”
Background
Metadata
- Authors
- Simpson, K., Leyendecker, P., Hopp, M., Müller-Lissner, S., Löwenstein, O., De Andrés, J., Troy Ferrarons, J., Bosse, B., Krain, B., Nichols, T., Kremers, W., & Reimer, K.
- Venue
- Current Medical Research and Opinion
- Publisher
- Informa UK Limited
- Published
- 2008-11-12
- Volume
- 24
- Issue
- 12
- Pages
- 3503-3512
- ISSN
- 0300-7995 (ISSN-L)
- 1473-4877
- OpenAlex
- W2124990868
- Cited by
- 177
- References
- 26
- FWCI
- 11.55
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.